Invitae shares have lost more than 80% over the past year and a half.
These 5 stocks from the maverick investor's flagship ARKK fund have gained a vote of confidence from analysts, with Wall Street predicting significant upside potential from current levels.
One of these stocks may be riskier than the other...
This biotech stock under $10 is the newest addition to Cathie Wood's flagship ARKK fund - and Wall Street analysts have high hopes for the shares, too.
NVTA earnings call for the period ending September 30, 2023.
The last two years have been tumultuous, and there are no calm waters in sight.
Invitae shares have dropped more than 60% this year.
/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar, M.D.,...
/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced results of its collaborative study on universal hereditary cancer...